CJC 1295 (mod GRF 1-29) 3 mg + Ipamorelin 4.5 mg Combo (Without Mannitol)

CJC-1295 triggers growth hormone (GH) release by stimulating the growth hormone releasing hormone receptor, distinguishing its mechanism from other methods. Its high selectivity has showcased favorable effects on bone health, lean body mass, insulin resistance, and muscle growth and development[][]. When combining these two peptides, it might yield amplified effects as they activate the growth hormone axis through distinct pathways. Utilizing both peptides in animal models could potentially exhibit increased benefits without substantially heightening side effects.

Ipamorelin is anticipated to elevate baseline GH levels, enabling CJC-1295 to generate both higher peaks and increased troughs while maintaining regular growth hormone pulsatile secretion. This combination could establish a heightened standard for the natural rise and fall of GH, leading to enhancements in lean body mass, improved muscle development, optimized insulin utilization, and overall better metabolic function.